Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On March 31, 2025, Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a front-runner in precision genetic medicine focused on rare diseases, announced the grant of equity awards to 39 newly hired individuals. This move is part of the company’s strategy to attract and retain top talent as it continues to expand its innovative programs. The grants were approved by the Compensation Committee of Sarepta's Board of Directors under the 2024 Employment Commencement Incentive Plan, and are in compliance with Nasdaq Listing Rule 5635(c)(4).

The new equity awards comprise options to purchase a total of 31,344 shares of Sarepta's common stock, alongside 77,442 restricted stock units (RSUs). The options feature an exercise price set at $63.82 per share, equivalent to the closing price of Sarepta's stock on the Grant Date.

The vesting schedule for the options is structured to incentivize long-term employment. Specifically, one-fourth of the shares underlying each employee’s option will vest on the first anniversary of the Grant Date. Following this initial vesting, an additional 1/48th of the shares will vest monthly, ensuring that all options granted will be fully vested by the fourth anniversary of the Grant Date, contingent upon the employees maintaining their positions at Sarepta.

Similarly, the RSUs will follow a yearly vesting schedule with one-fourth vesting on each anniversary of the Grant Date, leading to full vesting by the fourth anniversary, also subject to continued employment.

Sarepta Therapeutics remains dedicated to its mission of engineering precision genetic medicine aimed at rare diseases that severely impact lives, particularly focusing on conditions such as Duchenne muscular dystrophy and limb-girdle muscular dystrophies. With a robust portfolio of programs targeting muscle, central nervous system, and cardiac diseases, Sarepta continues to solidify its leadership position in the field.

As the company moves forward, the strategic hiring and subsequent equity grants are expected to bolster its innovative capabilities and enhance its workforce, ultimately contributing to advancements in treatment and patient outcomes.

The recent equity awards granted by Sarepta Therapeutics signal a strong commitment to its workforce and a strategic move to ensure the company remains at the forefront of genetic medicine. As the landscape of rare disease treatment continues to evolve, Sarepta’s focus on attracting skilled professionals will be crucial in achieving its ambitious goals and delivering on its promise to patients and families affected by rare diseases.

For more information about Sarepta Therapeutics and its initiatives, interested parties are encouraged to visit the company’s website or follow its social media channels.